HPLC Separation of Empty and Full AAV Capsids
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for determining the percent fraction of empty viral particles in AAV vector preparations are laborious, cumbersome, and low throughput, lacking effective separation and purification techniques to achieve high-quality standards for clinical use.
Innovation Solution
A method involving high-performance liquid chromatography (HPLC) with anion or cation exchange columns, using a discontinuous elution gradient and isocratic holds, to baseline separate and quantify empty and full AAV capsids, achieving high resolution and purity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional chromatographic methods are used to separate empty and full AAV particles, then purification is attempted, but baseline peak resolution between empty particles and full vectors is not achieved
Solution Approach 1:
The patent applies parameter changes by optimizing mobile phase composition (using specific buffers like Tris-HCl with NaCl gradients), adjusting pH levels (pH 7.0-9.0), modifying flow rates, and selecting specific column types (anion exchange or cation exchange) to achieve baseline separation between empty and full AAV particles while maintaining reasonable throughput
2Measurement precision
If laborious and cumbersome methods are used to determine empty viral particle fraction, then measurement accuracy may be improved, but analysis time and operational complexity increase
Solution Approach 1:
The patent replaces laborious manual separation and quantification procedures with an automated HPLC system that uses programmed mobile phase gradients and automated detection, thereby achieving accurate quantification of empty viral particles while significantly reducing analysis time and operational complexity
3Quantity of substance
If excess empty capsids are present in AAV vector preparations, then production yield is maintained, but immune response risk increases
Solution Approach 1:
The patent extracts and separates empty capsids from full AAV vectors using chromatographic methods, removing the harmful empty particles while retaining the therapeutic full vectors, thereby reducing immune response risk while maintaining production yield of functional vectors
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables accurate separation and quantification of empty and full AAV capsids, improving the quality of AAV vector preparations by reducing immune response risks and enhancing manufacturing efficiency.
Implementation Method 1
The method comprises running the viral preparation and a mobile phase through an ion (e.g., anion or cation) exchange column
Data Source
AI summary
The present disclosure provides methods for the separation and quantification of empty and full viral capsids (e.g., AAV capsids) within a viral preparation, such as a viral pharmaceutical composition or drug product.